Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolideR, 0.5 mg in Iranian MS patients during one-year follow-up. Methods: A multicenter, open-label, longitudi...

Description complète

Détails bibliographiques

Auteurs principaux:	Rozita Doosti, Abdorreza Naser Moghadasi, Amir Reza Azimi, Shahrokh Karbalai Saleh, Masoud Etemadifar, Vahid Shaygannejad, Fereshteh Ashtari, Mohammad Hossein Harirchian, Bahaadin Siroos, Hormoz Ayramloo, Nastaran Majdinasab, Seyyed Mohammad Masood Hojjati, Nabiollah Asghari, Seyed Mohammad Baghbanian, Hamed Cheraghmakani, Mahmoud Abedini, Behnaz Sedighi, Negar Mohseni Abbas abadi, Maedeh Ghasemitabar, Sara Talebianpour, Tohid Babayi Daylari, Vahid Dana, Neda Ghaleh noie, Mohammad Ali Sahraian
Format:	Artigo
Langue:	Inglês
Publié:	Babol University of Medical Sciences 2021-04-01
Collection:	Caspian Journal of Internal Medicine
Sujets:	fingolimod multiple sclerosis safety edss
Accès en ligne:	http://caspjim.com/article-1-2280-en.html
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!